NCT01230177View on ClinicalTrials.gov

Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)

CompletedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
ArthritisRheumatoid
Interventions
DRUG

etanercept (genetical recombination)

10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.

Trial Locations (1)

982-0032

Taihaku Sakura Hospital, Sendai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01230177 - Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan) | Biotech Hunter | Biotech Hunter